Matthew R. Porembka
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (10)
Supplementary Figure 1. ACTA2 expression was elevated in the molecular subtype with the worst prognosis (Group 4). Supplementary Figure 2. ACTA2 expression stratified by microsatellite stability status in the pooled cohort. Supplementary Figure 3. Alternatively tested thresholds to stratify patients into ACTA2-High and ACTA2-Low groups.Supplementary Figure 4. ACTA2 expression stratified by microsatellite stability status in the immune checkpoint inhibitor cohort.
Year:
2025
Supplementary Table 1. Univariable associations of the multivariable Cox proportional hazards model in the Yonsei cohort.Supplementary Table 2. Clinical characteristics of patients in the pooled validation cohort.Supplementary Table 3. Univariable associations of the multivariable Cox proportional hazards model of the pooled validation cohort.Supplementary Table 4. Univariable Cox proportional hazards regression of the association of individual genes of the 32-gene signature and their association with overall survival in the Yonsei cohort.Supplementary Table 5. Univariable Cox proportional hazards regression of the association of individual genes of the 32-gene signature and their association with overall survival in the pooled cohort.Supplementary Table 6. Multivariable analysis of the pooled cohort including microsatellite stability status.Supplementary Table 7. Multivariable analysis of the association of ACTA2 expression with recurrence-free survival in the pooled cohort.Supplementary Table 8. Clinical characteristics of patients treated with immune checkpoint inhibitors.Supplementary Table 9. ACTA2 expression in cells analyzed by single nuclear RNA sequencing cohort.Supplementary Table 10. Characteristics of patients analzyed by digital spatial transcriptomics.
Year:
2025
Purpose: To compare outcomes and molecular characteristics of patients who had surgery after neoadjuvant (NA) chemotherapy, with and without stereotactic ablative radiotherapy (SAbR), for pancreatic cancer. Insight could clarify the benefits of SAbR and provide molecular guidance for future therapeutic regimens. Experimental Design: This single-institution, tertiary care academic center cohort study included all patients diagnosed with pancreatic cancer between 2012 and 2023 treated with NA chemotherapy, with or without SAbR. We compared therapeutic responses, performed patient matching, and conducted Cox modeling to identify differences between groups. We assessed molecular response using RNA sequencing to identify SAbR-induced biologic differences. Results: Among 133 patients receiving chemotherapy and 48 receiving chemotherapy + SAbR, RNA sequencing was available for 29 and 14 patients, respectively. Despite more advanced baseline disease, the SAbR group showed better posttreatment pathology and similar overall survival [HR = 0.97, 95% confidence interval (CI), 0.58–1.60, P = 0.9]. Patient matching indicated that SAbR improved locoregional recurrence-free survival (HR = 0.24, 95% CI, 0.07–0.88, P = 0.009). Arterial involvement raised local failure risk with chemotherapy alone (HR = 3.37, 95% CI, 1.74–6.54, P P = 0.005). Gene set enrichment analysis showed immune activation, with CD8 and NK/NKT cell signatures associated with local control and Treg signatures associated with worse control. Conclusions: NA SAbR is associated with improved pathologic outcomes, enhanced local control, and maintained survival while inducing a distinct immune response. Well-powered studies are needed to clarify its clinical benefits.
Year:
2025
Purpose: We sought to identify biomarkers that predict overall survival (OS) and response to immune checkpoint inhibitors (ICI) for patients with gastric cancer. Experimental Design: This was a retrospective study of multiple independent cohorts of patients with gastric cancer. The association between tumor ACTA2 expression and OS and ICI response were determined in patients whose tumors were analyzed with bulk mRNA sequencing. Single-cell RNA sequencing (scRNA-seq) and digital spatial profiling data were used to compare tumors from patients with gastric cancer who did and did not respond to ICI. Results: Increasing tumor ACTA2 expression was independently associated with worse OS in a 567-patient discovery cohort [HR, 1.28 per unit increase; 95% confidence interval (CI), 1.02–1.62]. This finding was validated in three independent cohorts ( n = 974; HR, 1.52 per unit increase; 95% CI, 1.34–1.73). Of the 108 patients treated with ICI, 56% of patients with low ACTA2 expression responded to ICI versus 25% of patients with high ACTA2 expression ( P = 0.004). In an analysis of a publicly available scRNA-seq dataset of 5 microsatellite instability-high patients treated with ICI, the patient who responded to ICI had lower tumor stromal ACTA2 expression than the 4 nonresponders. Digital spatial profiling of tumor samples from 4 ICI responders and 5 ICI nonresponders revealed that responders may have lower ACTA2 expression in α-SMA–positive cancer-associated fibroblasts (CAF) than nonresponders (median: 5.00 vs. 5.50). Conclusions: ACTA2 expression is associated with survival and ICI response in patients with gastric cancer. ACTA2 expression in CAFs, but not in other cellular compartments, appears to be associated with ICI response.
Year:
2025
PURPOSE: Previous studies have shown health disparities among US-Mexico border county (BC) residents. However, the impact of BC residence on gastric cancer treatment and survival outcomes is unknown. Our study compares the receipt of guideline-concordant care (GCC) and survival for patients with gastric cancer by BC status. METHODS: We conducted a retrospective review of adult non-Hispanic White and Hispanic patients with gastric adenocarcinoma diagnosed between 2004 and 2017 in the Texas Cancer Registry. Chi-square tests were used to compare categorical group differences, with pooled t-tests used to compare group means. The impact of BC residence on likelihood of receiving GCC was assessed with logistic regression. Overall survival was estimated using the Kaplan-Meier method and compared with log-rank tests. RESULTS: Our cohort consisted of 12,514 patients (15% BC). Overall, 45% of nonborder county residents received GCC versus 35% of BC residents ( P < .0001). After adjusting for age, race, stage, and insurance status, BC patients remained significantly less likely to receive GCC (odds ratio 0.69; 95% CI, 0.61 to 0.78). BC residence was associated with increased hazard of all-cause mortality after accounting for age, race, stage, poverty index, and treatment receipt (hazard ratio 1.11; 95% CI, 1.04 to 1.18). BC residents had significantly worse overall survival for localized and regional disease. CONCLUSION: BC residents with gastric cancer are less likely to receive GCC and have significantly worse survival outcomes than nonborder county residents. This highlights significant health care disparities arising from the lack of health care access and multiple social determinants of health. Further studies are needed to identify specific contributing mechanisms to improve health care equity.
Year:
2022
Year:
2020
Year:
2020
Year:
2020
Year:
2020
Year:
2020
Collaborators (16)
Zhikai Chi
University of Texas Southwestern Medical Center
Cheryl Lewis
Associate Professor
University of Texas Southwestern
Todd Aguilera
University of Texas Southwestern Medical Center
Jae-Ho Cheong
Professor
Yonsei University College of Medicine
John Mansour
Professor
University of Texas Southwestern Medical Center
Sung Hak Lee
associate professor
Catholic University of Korea School of Medicine
Adam Yopp
Professor of Surgery
University of Texas Southwestern Medical Center
Song Zhang
-
Ahmed M. Elamir
Assistant professor (tenure track)
East Carolina University
David Hsiehchen
University of Texas Southwestern Medical Center
Syed Kazmi
Assistant Professor
University of Texas Southwestern Medical Center
Tae Hyun Hwang
Professor
Vanderbilt University Medical Center
Sam Wang
University of Texas Southwestern Department of Surgery
Patricio M. Polanco
Professor
-
Herbert Zeh
Chair of Surgery
University of Texas Southwestern Medical Center
Nina N Sanford
University of Texas Southwestern
Make your next move.
Prepare your application
Review drafts before you send them.